

1 **TITLE PAGE**

2

3 **Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor**

4 **Kidneys Predict 12-Month Posttransplant Outcome**

5

6 **Authors:** Philip D Charles<sup>1,2†</sup>, Sarah Fawaz<sup>3,4\*</sup>, Rebecca H Vaughan<sup>3,4\*</sup>, Simon Davis<sup>2</sup>, Priyanka  
7 Joshi<sup>3</sup>, Iolanda Vendrell<sup>2</sup>, Ka Ho Tam<sup>5</sup>, Roman Fischer<sup>2</sup>, Benedikt M Kessler<sup>2</sup>, Edward J  
8 Sharples<sup>6</sup>, Alberto Santos<sup>1,7,8</sup>, Rutger J Ploeg<sup>3,4</sup>, Maria Kaiser<sup>3,4†</sup>

9

10 **Affiliations:**

11 <sup>1</sup>Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United  
12 Kingdom.

13 <sup>2</sup>Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine,  
14 University of Oxford; Oxford, United Kingdom.

15 <sup>3</sup>Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.

16 <sup>4</sup>Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University  
17 of Oxford; Oxford, United Kingdom.

18 <sup>5</sup>Engineering Department, University of Oxford; United Kingdom.

19 <sup>6</sup>University Hospital Oxford; Oxford, United Kingdom.

20 <sup>7</sup>Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.

21 <sup>8</sup>Novo Nordisk Foundation Center for Protein Research, University of Copenhagen;

22 Copenhagen, Denmark.

23 \*These authors contributed equally.

24

25 †Corresponding authors. Email: [philip.charles@ndm.ox.ac.uk](mailto:philip.charles@ndm.ox.ac.uk); [maria.kaisar@nds.ox.ac.uk](mailto:maria.kaisar@nds.ox.ac.uk)

26

27 **Keywords:**

28 Kidney transplantation, Machine Learning, Data Independent Acquisition, Proteomics, Donor

29 age, QUOD

30

31 **ABSTRACT**

32 Organ availability limits kidney transplantation, the best treatment for end-stage kidney  
33 disease. Deceased donor acceptance criteria have been relaxed to include older donors with  
34 higher risk of inferior posttransplant outcomes. More granular prediction models, based on  
35 deeper resolution organ assessment and understanding of damage processes, could substantially  
36 improve donor organ allocation and reduce graft dysfunction risk. Here, we profiled pre-  
37 implantation kidney biopsy proteomes from 185 deceased donors by high-resolution mass  
38 spectrometry and used machine learning to integrate and model these data, and donor and  
39 recipient clinical metadata to predict outcome. Our analysis and orthogonal validation on an

40 independent cohort revealed 136 proteins predictive of outcome, 124 proteins of which showed  
41 donor-age modulated predictive effects. Observed associations with inflammatory, catabolic,  
42 lipid metabolism and apoptotic pathways may predispose donor kidneys to suboptimal  
43 posttransplant outcomes. Our work shows that integrating kidney proteome information with  
44 clinical metadata enhances the resolution of donor kidney quality stratification, and the  
45 highlighted biological mechanisms open new research directions in developing interventions  
46 during donor management or preservation to improve kidney transplantation outcome.

47

## 48 **TRANSLATIONAL STATEMENT**

49 We profiled the proteome of pre-implantation biopsies selected from donor kidneys on  
50 the basis of paired 12-month graft function. Our data reveal a signature of proteins which  
51 contribute to transplant outcomes, many of these show different strengths of association  
52 dependent on donor age. The biological themes of the identified candidates reinforce immuno-  
53 metabolic and catabolic mechanisms as potential contributors to donor kidney susceptibility that  
54 may reduce graft recovery after transplantation.

55

## 56 **INTRODUCTION**

57 Kidney transplantation is the optimal treatment for end-stage kidney disease. Compared  
58 to dialysis, transplantation increases life-expectancy, improves quality of life and is cost-  
59 effective. Limited availability of suitable donor kidneys impedes treatment of chronic kidney  
60 disease, and often prolongs dialysis, increasing morbidity and mortality. Deceased donor organ  
61 shortages, living donation decline in some countries and emerging ageing populations drive

62 increased utilization of older deceased donor kidneys, now comprising more than half of offered  
63 organs<sup>1,2</sup>.

64 Ageing associates with time-dependent decline of organ function, evidenced in kidneys  
65 by histologic lesions, such as tubular atrophy, interstitial fibrosis, glomerulosclerosis, and  
66 arteriosclerosis. Older kidneys demonstrate fewer functioning glomeruli, less renal mass,  
67 podocyte dysfunction, and impaired cellular repair<sup>3</sup>. Glomerular diseases are more common and  
68 associated with worse outcomes in older patients<sup>4</sup>. Age accelerates the transition from Acute  
69 Kidney Injury (AKI) to chronic injury<sup>5</sup> and is an independent risk factor of graft dysfunction and  
70 loss for deceased donor kidneys<sup>6</sup>; furthermore, older donors are more likely to suffer from  
71 additional risk factors such as diabetes, hypertension or cardiovascular disease.

72 Donor age is incorporated in clinical scoring algorithms to inform kidney allocation  
73 decisions<sup>7,8</sup>, but is insufficient to consistently predict transplant outcomes. Current front-line  
74 models incorporating further clinical factors such as terminal serum creatinine, history of  
75 hypertension and diabetes<sup>8,9</sup> show consistent performance across demographics but lack granular  
76 predictive accuracy<sup>10</sup>.

77 Molecular analyses of biopsies plausibly offer higher resolution assessment of organ  
78 state; but require ‘big picture’ understanding of mechanisms associated specifically with poor  
79 outcome, rather than immediate (but potentially recoverable) acute injury. Deceased donors are  
80 frequently assessed as having sustained damage (i.e. AKI) based on serum creatinine levels<sup>14</sup>,  
81 however this metric poorly associates with longer term outcomes<sup>13-16</sup>.

82 Mass spectrometry (MS) proteomic studies can provide such a ‘big picture’, but have  
83 heretofore lacked cohort capacity to represent demographic diversity<sup>17</sup>. Advances in high-  
84 throughput techniques<sup>18</sup> now allow sensitivity and depth without sacrificing throughput capacity.

85 Developments in machine learning and nonlinear regression analyses furthermore offer tools to  
86 extract maximal knowledge from limited size experimental cohorts, with applications in disease  
87 staging, disease recurrence prediction, treatment response monitoring, and biomarker  
88 identification<sup>19,20</sup> .

89 Integration of deep proteomic profiles with heterogenous clinical and demographic  
90 factors using modern statistical tools can empower the next steps toward precision medicine<sup>21</sup> .  
91 Here, we benefit from the granularity provided by our MS-based proteomic profiling to report  
92 age- and immunometabolism-related proteomic signatures in pre-implantation kidney biopsies  
93 associated with transplant outcomes.

94

## 95 **METHODS**

### 96 **Study Design**

97 Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample excluded during  
98 data processing) were obtained from the Quality in Organ Donor (QUOD) biobank, a national  
99 multi-center UK wide bioresource of deceased donor clinical samples acquired during donor  
100 management and organ procurement. Biopsies were obtained from Donation after Brain Death  
101 (DBD) donors and Donation after Circulatory Death (DCD) donors at the back table immediately  
102 after kidney procurement.

103 Selection of biopsies was based on paired 12-month post-transplant outcomes. To  
104 minimize the impact of recipient factors, we only included kidneys for which the contralateral  
105 kidney was transplanted with similar outcome. Kidneys were selected to cover the outcome  
106 continuum i.e. the range of estimated Glomerular Filtration Rate (eGFR) in the recipient at 12

107 months posttransplant, from primary non-function to eGFR>80 ml/min/1.73 m<sup>2</sup>, excluding  
108 extreme demographic or clinical factors where possible. Samples were linked to corresponding  
109 donor and recipient demographic and clinical metadata, provided by NHS Blood and Transplant  
110 National Registry.

## 111 **Study Approval and Ethics statement**

112 Informed consent from donor families was obtained prior to sample procurement.  
113 Collection of QUOD samples and research ethics approval was provided by QUOD  
114 (NW/18/0187).

## 115 **Experimental Protocols and Statistical Analysis**

116 See Supplementary Methods.

117

## 118 **RESULTS**

### 119 **Donor clinical and demographic variable relevance for eGFR at 12-month posttransplant**

120 For exploratory analysis, we considered eGFR values in two ways. Firstly, to compare  
121 clinical factors, we grouped 12 month posttransplant outcomes into tertiles; Suboptimal Outcome  
122 (SO; eGFR≤39), Intermediate Outcome (IO; 40<eGFR≤59), and Good Outcome (GO;  
123 eGFR≥60), all units ml/min/1.73 m<sup>2</sup> (Figure 1). We refer to this henceforth as ‘stratified eGFR’.  
124 Secondly, all eGFR values (both recipient and donor) were rank-transformed so that we could  
125 model against a continuum of outcomes while mitigating extreme values, or values recorded as 0  
126 due to graft failure. We refer to ‘ranked eGFR’ henceforth to indicate ranked recipient eGFR at  
127 12 months posttransplant.

128 Clinical metadata illustrated that stratified eGFR donor groups gave a balanced  
129 representation of the UK donor population (Table 1), with no significant association between  
130 donor type (DBD/DCD) and ranked eGFR (t-test;  $p=0.2028$ ). We investigated associations  
131 between clinical variables and stratified eGFR subgroups within each donor type, and between  
132 donor types within stratified eGFR subgroups (Supplementary Table 1). There was a significant  
133 difference in the current front-line selection score, the UK Kidney Donor Risk Index (UKKDRI)<sup>8</sup>  
134 between outcome groups across donor types (ANOVA F-test; DBD:  $p=1.298e-6$ ; DCD:  
135  $p=3.946e-7$ ). In both donor types, the major component of UKKDRI, donor age, was  
136 significantly different between outcome subgroups with donor age in SO being older (ANOVA  
137 F-test; DBD:  $p=1.253e-9$ ; DCD:  $p=1.196e-7$ ). Histories of hypertension (also a component of  
138 UKKDRI) were different between subgroups in DBD (ANOVA F-test; DBD:  $p=0.0020$ ; DCD:  
139  $p=0.1069$ ). Histories of diabetes (used in the US risk index, but not UKKDRI) were not  
140 significantly different (ANOVA F-test;  $p=0.6188$ ; DCD:  $p=0.2348$ ). Terminal serum creatinine  
141 levels were similar across outcome subgroups (ANOVA F-test; DBD:  $p=0.6972$ ; DCD:  
142  $p=0.6448$ ), although within the GO group it was higher in DBD than in DCD (t-test;  $p=0.0443$ ).

143 After imputation of missing values, we examined associations between clinical variables  
144 common to both DBD and DCD donors (Figure 2). The strongest associations with ranked eGFR  
145 were donor age (Pearson's  $r=-0.52$ ), and recipient age ( $r=-0.28$ ). Donor history of hypertension  
146 and cardiological disease also clustered closely due to correlation with donor age ( $r=0.35$  and  
147  $r=0.33$  respectively) but had a weaker direct correlation with outcome ( $r=0.30$  and  $r=0.23$   
148 respectively).

## 149 **Unsupervised analysis of pretransplant kidney proteomes**

150 Proteomic analysis quantified 2984 protein groups with 50% or less missing values (out  
151 of 7790 identified protein groups in total) over 185 samples and 20 interspersed sample pools  
152 (Supplementary Figure 1A). Analysis of sample pools showed minimal technical variance across  
153 sample acquisition (squared mean pairwise Z-corrected Pearson's  $r=0.94$ ). Six samples were  
154 paired biopsies from the left and right kidneys of three donors. These samples showed high  
155 correlation of protein intensity values between donor pairs (Pearson's  $r=0.71, 0.92$  and  $0.91$ ;  
156 Supplementary Figure 1B).

157 We explored the proteomic data using Principal Component Analysis (PCA) to find  
158 underlying linear trends. Sample variance concentrated in the first two principal components  
159 (PC1: 20.01%; PC2: 13.38%; Figure 3A). K-means clustering identified 4 distinct clusters  
160 (Figure 3A) whose membership associated with donor type, with a preponderance of DBD  
161 samples towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure 3B,  
162 upper left panel;  $p=0.0235$ ). Clustering did not associate strongly with recipient ranked eGFR  
163 ( $p=0.4134$ ), nor with donor ranked eGFR ( $p=0.1684$ ), or donor age ( $p=0.7907$ ) (Figure 3B, upper  
164 middle, upper right and lower left panels). There was a weakly significant association between  
165 cluster membership and donor BMI ( $p=0.0350$ ) and with serum creatinine ( $p=0.0326$ ) (Figure  
166 3B, lower middle and lower right panels).

### 167 **Integration of kidney proteomes with clinical metadata enhances the resolution of donor** 168 **kidney quality stratification**

169 To identify possible clinical variable-protein interaction relationships with outcome, we  
170 used machine learning (Prediction Rule Ensembles<sup>22</sup>; PRE) to select features from the set of  
171 quantified proteins and all donor type-independent clinical variables.



172 We split our data into training and test sets, excluding the six paired kidneys, and  
173 sampling equally across stratified eGFR using a 2/3:1/3 train:test split. Test data was only used  
174 for validation (see below). The six paired kidneys were reserved as a second ‘biological  
175 duplicates’ test set.

176 A PRE model finds a minimal predictor set in the form of decision tree, linear regression  
177 and multivariate adaptive regression spline<sup>24</sup> rules, but does not yield an exhaustive list of  
178 predictors. We performed PRE iteratively, modelling against ranked eGFR; any proteins  
179 identified in the final ensemble model of any iteration were excluded from the dataset in future  
180 iterations, retaining only non-identified proteins plus all clinical variables. 2000 iterations of  
181 PRE generated 3282 rules across all ensembles. The most common rules involved donor age,  
182 featuring as a term in 3154 (~96.1%) rules; in comparison, protein terms (collectively) featured  
183 in 198 (~6.0%) rules, while the next largest non-protein term was donor group, featuring in 5  
184 (~0.1%) rules (Figure 4A). Feature selection became progressively inefficient, in terms of  
185 candidate yield per iteration, however new candidates were still found up to termination at  
186 iteration 2000. This process generated 195 candidate proteins; we supplemented this list with  
187 proteins that had high correlation (Pearson’s  $r > 0.65$ ) with any of those candidates; bringing the  
188 final list up to 255 candidates.

### 189 **Regression spline modelling reveals protein associations with posttransplant outcome are** 190 **modulated by donor age**

191 Next, we tested each protein candidate for individual association with outcome. Since  
192 eGFR rank transformation is cohort specific, to generate results which generalized to other  
193 settings we modelled against an outcome binary, calibrated against a population-level threshold.  
194 Based on UK Renal Registry data, the donor type-weighted average median eGFR at 12 months

195 posttransplant since 2013<sup>25</sup> was approximately  $\sim 50.25$  ml/min/1.73 m<sup>2</sup> ( $\pm 0.24$  standard error; );  
196 for simplicity we used a threshold of 50 ml/min/1.73 m<sup>2</sup>. We refer to ‘sub-median outcome’  
197 henceforth to refer to recipient eGFR at 12 months posttransplant less than 50 ml/min/1.73 m<sup>2</sup>.

198 Using multivariate adaptive regression spline modelling<sup>23</sup> to assess individual protein  
199 relationships, we generated predictive models for sub-median outcome using each protein, donor  
200 age, and age:protein interaction. This was performed in a regularized framework to retain only a  
201 minimal set of predictors in each model. We discarded candidates whose model either did not  
202 feature a protein or age:protein term, or gave a worse prediction error (Brier score<sup>26</sup>) than donor  
203 age alone.

204 After filtering we had identified 136 proteins which predicted sub-median outcome  
205 (Supplementary Table 2). We performed a network analysis of shared Reactome pathways  
206 (Figure 4). Walktrap clustering revealed 4 major clusters of shared-pathway proteins (Table 2);  
207 Immune Regulation and Complement Activation, Protein Metabolism and Regulation,  
208 Metabolism and Apoptosis.

209 For 124 proteins, the model included an age:protein interaction term where the predictive  
210 effect of protein abundance was modulated by age, independent of the effect of age alone or  
211 protein abundance alone (Figure 5, Supplementary Table 2). To visualize these effects, we used  
212 each model to predict outcomes across increasing donor age for a high (90<sup>th</sup> percentile), median  
213 and low (10<sup>th</sup> percentile) protein abundance (Figure 5A and Supplementary Figure 2). The  
214 majority of proteins were positively associated with the chance of sub-median outcome  
215 (simplistically, more protein = worse outcome), with the effect appearing to increase up to  
216 around donor age 45-55, including representative proteins for all four major clusters including  
217 known markers Cystatin-C (CST3; nephron function) and Vitronectin (VTN; fibrosis) as well as

218 a protein known for age-modulated disease associations, Apolipoprotein E (APOE). Several  
219 proteins were negatively associated with the chance of sub-median outcome (simplistically more  
220 protein = better outcome), with the largest effects shown by MAP2K1 and SLC27A2, the latter  
221 in particular being modelled as having minimal effect in donors younger than 40. The selection  
222 and filtering steps are summarized in Figure 5B.

### 223 **Orthogonal validation confirms model performance, including age-modulated immuno-** 224 **metabolic impact on transplant outcomes**

225 We adopted two orthogonal validation approaches. Firstly, we assessed the performance  
226 of each model on test data. Going from train to test data, the models showed a small increase in  
227 accuracy (Brier score; mean square error) and a small decrease in overall predictive performance  
228 as measured by the area under the curve (AUC) (Figure 6A), indicating that the models  
229 generalized well to unseen data, with most of the models (~110/136) showing almost no  
230 degradation in performance.

231 Secondly, we selected several cluster-representative proteins (VTN, APOE, CST3 and  
232 Prolactin Regulatory Element Binding; PREB) that had robust available antibodies (Figure 6B).  
233 We investigated the predicted pattern of associations between protein abundance and outcome  
234 (Figure 6C), by performing western blot validation of our results (Figure 6D). Selecting samples  
235 with remaining material from our cohort from the Good and Suboptimal Outcome stratified  
236 eGFR tertiles of our sample set, we compared protein abundance between younger (oldest  
237 sample 49) and older (youngest sample 58) donors. Our results were broadly consistent with the  
238 associations anticipated by our modelling:

239 For VTN, our model suggests a strong association between protein abundance and  
240 outcome in younger donors that strengthens towards age 40-50 and then weakens. We observed a

241 significant difference in abundance by western blot between GO and SO outcome strata in  
242 younger donors (t-test;  $p=2.107e-9$ ) and a weaker but mildly significant difference in older  
243 donors (t-test;  $p=0.0245$ ).

244 For PREB, the model suggests that the age of maximum difference is shifted towards  
245 older donors compared to VTN; we did not observe any significant difference by western (t-test;  
246  $p=0.4530$ ) in young donors but did find such a difference in older donors (t-test,  $p=8.800e-5$ ).

247 For APOE, the model suggests that the strongest association is over the middle of the age  
248 range, where outcome changes rapidly with donor age, followed by a weaker but consistent  
249 association from donor age 49-50 onwards. We observed no difference among younger donors,  
250 although examination of the sampled age ranges indicate the area of starkest difference was  
251 under-sampled (Figure 5C; t-test,  $p=0.3719$ ). In older donors, we saw a mildly significant  
252 difference in APOE abundance between outcomes (t-test,  $p=0.0323$ ).

253 For CST3, the model again predicted a strong association in young donors which then  
254 weakens (and even reverses, such that GO samples would tend to have higher CST3 than SO  
255 samples); in younger donor western blots we observed a significant difference (t-test,  $p=0.0084$ )  
256 between GO and SO, while in older donors we saw a nonsignificant difference, but (in contrast  
257 to the prediction) still with a positive median protein abundance difference from GO to SO.

258 Finally, we compared the predicted outcome for each of the six paired kidneys from the  
259 second 'biological duplicates' test set against their actual recipient eGFR at 12 months  
260 posttransplant (Figure 6E). All three kidney pairs in this dataset had consistent outcomes across  
261 pairs; two pairs with sub-median outcome (15 and 36 ml/min/1.73 m<sup>2</sup>; 23 and 27 ml/min/1.73  
262 m<sup>2</sup>) and one pair with above-median outcome (72 and 81 ml/min/1.73 m<sup>2</sup>); all four protein  
263 models assigned the four kidneys from the two sub-median outcome donors a probability of sub-

264 median outcome greater than 0.6 (except in one case for PREB, where it was 0.48), and assigned  
265 both kidneys from the above-median outcome donor a probability of sub-median outcome less  
266 that 0.3.

## 267 **DISCUSSION**

268         Increasingly, shortages of optimal organs require utilization of kidneys from older  
269 deceased donors with increased risks of graft failure or functional decline. Here, we show that  
270 age-modulated kidney proteomic profiles improve risk stratification of donor kidney quality,  
271 revealing clinically relevant age-protein interaction effects.

272         Donor age remains a key contributor in these clinical decisions and is rightfully one of  
273 the most strongly weighted terms in extant scoring systems to determine kidney allocation<sup>8,27</sup>. In  
274 our analysis, we found no obvious difference according to age when comparing donor kidney  
275 proteomes by unbiased PCA. However, looking specifically at *outcomes*, it was the single most  
276 important factor. PCA considers only a linear combination of variables and is ill-suited to  
277 exploring nonlinear effects or interaction between variables. When we explored our data with our  
278 iterative PRE feature selection approach, a substantial number of proteins were revealed to be  
279 relevant.

280         The effect of donor age is not a novel finding, but integration of the age and proteomic  
281 information resulted in enhanced prediction of 12 month sub-median function without reference  
282 to other currently considered clinical factors. In particular, a factor often described as relevant to  
283 transplant outcome is donor type<sup>28</sup>. This is true at a clinical level in terms of donor management,  
284 and donation after circulatory death is considered an adverse factor for transplant outcome in the  
285 US<sup>7</sup> (although not in the UK<sup>8,29</sup>). Our initial PCA analysis found that non-supervised clustering  
286 of the sample proteomes did partially separate samples by type but did not extend to association

287 with outcome. Weaker association may be obscured by factors associated with the overwhelming  
288 effect of donor age, but (without disputing donor type-specific mechanisms of kidney injury<sup>30</sup>),  
289 our data are consistent with the idea that extent of injury (rather than the cause) is the primary  
290 contributor towards recovery potential<sup>31</sup>.

291 Within our final list of 136 proteins associated with outcome there is a common theme of  
292 implication in immune response to kidney injury (including both chronic injury, and acute  
293 injury) particularly as a result of ischemic metabolic disruption. Our analysis of proteins  
294 associated with outcome also revealed that most (124/136) proteins showed age-moderated  
295 differences in their effect; for most proteins manifesting as a stronger negative association  
296 between abundance and outcome starting around donor age 40-50. This second-order age  
297 interaction effect, where weightings of other factors are themselves age dependent, has not (to  
298 our knowledge) been explored in transplantation, and may be key to fully understanding the  
299 effects of molecular predictors.

300 A prominent age-modulated example of a chronic injury associated marker in our  
301 candidate list is VTN, a primary component of the extracellular matrix involved in in cell  
302 adhesion, enhancing the activity of plasminogen activator inhibitor-1 and inhibition of the  
303 terminal complement pathway<sup>32</sup>. Vitronectin has been suggested as a biomarker of kidney  
304 fibrosis, although the mode of its multifaced action needs further investigation<sup>33</sup>. Further acute  
305 injury associated markers include components of the membrane attack complex, C5 (in the form  
306 of C5b cleavage product) and C8A, which has been associated with tissue injury resulting from  
307 ischemia/reperfusion<sup>34,35</sup>, Complement Component 1r (C1R), part of the activation complex for  
308 the classical complement pathway<sup>36</sup>, and Complement Factor B (CFB), a component of the  
309 alternative pathway. Another candidate associated with immune regulation is Maltase

310 Glucoamylase (MGAM), characterized as an intestinal enterocyte but with expression in several  
311 tissues including kidney, and whose presence in urinary exosomes been cited as a marker of AKI  
312 in cirrhosis patients<sup>37</sup>.

313 Mitogen-activated protein kinase 1 (MAP2K1, aka MEK1), a key component of the MAP  
314 kinase signal transduction pathway and closely involved in both cellular control and immune  
315 regulation (as part of TNF $\alpha$  signaling response<sup>38</sup>), is notable as one of the few proteins for which  
316 higher abundance was associated with a reduced probability of sub-median outcome, indicating  
317 resilience to injury. Increased TNF $\alpha$  is more usually associated with renal injury<sup>39</sup>, so this result  
318 is counterintuitive. The MAPK/ERK cascade impacts many regulatory pathways so it is  
319 reasonable to assume such intuition may oversimplify the effect of increased MEK1 abundance.

320 Several age-moderated proteins we report are characterized as markers of protein  
321 regulation and proteasomal activity, suggesting alterations within the proteostasis network that  
322 increase susceptibility of donor grafts to subsequent injury and reduce capacity for recovery.  
323 CST3 is particularly noteworthy as, measured in serum, it is a known and effective general  
324 biomarker for kidney function and has previously been reported as having predictive power for  
325 outcomes in transplant recipients<sup>40-42</sup>. Our evidence indicates a further association between  
326 CST3 levels in the donor kidney tissue and outcome; moreover, that this effect is age dependent,  
327 starting around age 40. Interestingly, while serum CST3 is relatively independent of age in  
328 children and young adults<sup>43</sup>, there is some evidence for an increase in later years<sup>44</sup>.

329 We found the age-modulated candidate PREB (Prolactin Regulatory Element Binding  
330 protein) biologically interesting for three reasons. Firstly, there is a well characterized  
331 relationships between kidney dysfunction (in the form of CKD), cardiovascular disease and  
332 prolactinemia<sup>45</sup>, with CKD patients being associated with elevated prolactinemia. Secondly, it is

333 a regulator of glucose homeostasis in the liver and therefore a plausible key node for metabolic  
334 regulation in kidneys as well<sup>46</sup>, acknowledging the large emphasis in our pathway analysis on  
335 metabolic functions. Thirdly, it has a predicted<sup>47</sup> role in exit from the endoplasmic reticulum and  
336 the unfolded protein response, which has an association with CKD via NFκB -mediated  
337 inflammation<sup>48</sup>.

338 Another age-moderated protein, APOE, stands out as having previously reported genetic  
339 allele age-related associations with disease and organ dysfunction including risk of Alzheimer's  
340 Disease (AD)<sup>57</sup> (with the strongest effect manifesting around age 65<sup>58</sup>), macular dysfunction,  
341 atherosclerosis and pulmonary scarring<sup>59,60</sup>, and evidence for shared allele risk across diseases<sup>61</sup>.  
342 In kidneys, APOE plays an important role in lipid metabolism to regulate the growth and  
343 survival of mesangial cells and preserve organ function<sup>49</sup>; it is a marker for outcome in transplant  
344 recipients<sup>50-52</sup>, and there is already evidence for *APOE* genetic allele association with kidney  
345 dysfunction risk<sup>53-55</sup>, possibly manifested by lipidomic differences between allelic profiles<sup>56</sup>. We  
346 have previously observed small (not statistically significant) increases in APOE due to ischemic  
347 reperfusion injuries<sup>62</sup> possibly explained by a recent description of the role of APOE in  
348 mediating senescence<sup>63</sup>. Such evidence supports further in-depth investigation of the *APOE*  
349 genotype in outcomes across donor kidney age. There is existing evidence for similar allele  
350 dependent transplant outcome effects in another apolipoprotein (APOL1)<sup>64</sup>, suggesting that the  
351 broader apolipoprotein allelic profile may play an important role in outcome.

352 Our list of outcome-associated candidates, controlling for the effect of donor age,  
353 including those for which we report a further age-moderated effect, cannot be exhaustive.  
354 Practicalities of sample acquisition limited sampling of a wide range of outcomes outside the 30-  
355 60 donor age range, especially limited good outcome events at high donor age. Organ allocation



356 algorithms impose a close link between donor and recipient age in the sample cohort, so while  
357 we interpret these age-moderated effects in terms of organ resilience in older donors, it could  
358 also represent a greater ability to repair a given level of damage in younger recipients. Further,  
359 we consider only chronological donor age, rather than a more nuanced representation of the  
360 epigenomic biological clock<sup>65</sup>, which may to account for some variation observed with respect  
361 to both donors and recipients.

362 In the vast majority of proteins, the modelling suggests a plateauing effect at high donor  
363 age where the differences in outcome due to both protein and age are smaller. This effect may be  
364 an artifact of the distribution of sub-median outcomes in our UK population-representative data  
365 (>95% sub-median outcome above age 60 in our training set). The protein abundance differences  
366 between GO and SO outcomes in our western blot validation were broadly consistent with our  
367 differences expected given our prediction models. There were some differences; firstly, the  
368 differences in both VTN and PREB in older donors were larger than might be expected by  
369 examination of the prediction curves (Figure 6B, upper panel); secondly, the prediction for CST3  
370 of a small reversal of the effect is both unexpected and biologically counterintuitive. Both  
371 examples are most readily explained as model artifacts due to lack of outcome diversity at high  
372 age ranges.

373 It is immediately clear from our results that the strength of the donor age factor is  
374 enormous relative to any other protein or clinical effect; this age effect is liable to dominate any  
375 prediction weighting and reduce the accuracy of estimated protein contribution. A much larger  
376 cohort could mitigate this issue. Advances in high-throughput proteomics techniques continue to  
377 increase feasible cohort sizes<sup>66</sup> but fundamental limitations on organ acquisition remain.  
378 Archiving at scale of clinical samples in bioresources such as the QUOD biobank to parallel

379 advancements in big data analysis and interpretation platforms is therefore necessary for future  
380 development of granular evidence-based decision making.

381 In this work, we profiled the proteome of pre-implantation biopsies selected from donor  
382 kidneys on the basis of paired 12-month graft function. Using machine learning and regression  
383 models, we identified 136 proteins associated with sub-median outcomes, suggesting molecular  
384 signatures which may refine models of graft dysfunction based on clinical and demographic  
385 factors alone. We also found that most of these proteins furthermore show donor-age modulated  
386 association. The biological themes of the identified proteins reinforce known immuno-metabolic  
387 mechanisms of kidney injury but raise interesting possibilities for further work, especially with  
388 regard to donor genetic background, and also suggest that the possibility of donor age-moderated  
389 weighting should be considered as a matter of course in future work.

390

## 391 **SUPPLEMENTARY MATERIALS**

392 Supplementary Methods

393 Supplementary Table 1: Clinical variable p-values for association with donor type and outcome

394 Supplementary Table 2: Summary of results for all candidate proteins

395 Supplementary Figure 1: Protein quantification quality

396 A: Missingness comparison: Proteins are shown ranked by the number of missing values  
397 across all samples and the twenty standard pools, excluding one run which was removed  
398 due to low signal. 2984 proteins had missing values in 50% or less runs.

399 B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)  
400 from 3 individual donors were compared, as these are effectively biological replicates. x  
401 axes: value in left kidney. y axes: value in right kidney. Inset: R-squared value

402 Supplementary Figure 2: Prediction of sub-median outcome differences between high and low  
403 protein across donor age, for all shortlisted proteins with a predicted age modulation effect  
404 Black traces: prediction at median protein abundance. Purple trace: prediction at 90th  
405 percentile of protein abundance. Orange traces: prediction at 10th percentile of protein  
406 abundance. The corresponding point on the main figure thus indicates the age at which  
407 the difference between orange and purple lines is greatest.

408

#### 409 **DATA AND MATERIALS AVAILABILITY**

410 The mass spectrometry proteomics data have been deposited to the ProteomeXchange  
411 Consortium via the PRIDE <sup>67</sup> partner repository with the dataset identifier PXD033428.

412

#### 413 **DISCLOSURE AND FUNDING**

414 This study was supported by NHS Blood and Transplant funding awarded to MK & RJP. SF  
415 was supported by Kidney Research UK, grant reference KS\_RP\_002\_20210111 awarded to MK.  
416 PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to  
417 BMK. Authors declare that they have no competing interests.

#### 418 **Author contributions:**

419 Conceptualization: MK

420 Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK

421 Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS

422 Visualization: PDC

423 Funding acquisition: BMK, RJP, MK

424 Project administration: MK  
425 Supervision: RF, AS, MK  
426 Writing – original draft: PDC, ES, MK  
427 Writing – review & editing: All authors

428

## 429 REFERENCES

- 430 1. Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early  
431 Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme.  
432 *Transplantation*. 2017;101(12):2888-2897. doi:10.1097/TP.0000000000001860
- 433 2. Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation  
434 rates in the UK reveal marked regional variation and highlight the potential for increasing  
435 kidney donation: a prospective cohort study†. *Br J Anaesth*. 2014;113(1):83-90.  
436 doi:10.1093/bja/aet473
- 437 3. Denic A, Glasscock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic  
438 Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821
- 439 4. O’Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. *J*  
440 *Am Soc Nephrol*. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422
- 441 5. Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among  
442 Elderly. *J Am Soc Nephrol*. 2009;20(1):223-228. doi:10.1681/ASN.2007080837
- 443 6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor  
444 age and cold storage time on outcome in recipients of kidneys donated after circulatory death  
445 in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S0140-  
446 6736(12)61685-7
- 447 7. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for  
448 deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236.  
449 doi:10.1097/TP.0b013e3181ac620b
- 450 8. Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index  
451 for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*.  
452 2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4
- 453 9. Neuberger J, Callaghan C. Organ utilization - the next hurdle in transplantation? *Transpl Int*.  
454 2020;33(12):1597-1609. doi:10.1111/tri.13744
- 455 10. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor  
456 risk indices for deceased donor kidney transplant survival in the Australian and New Zealand  
457 population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090

- 458 11. Remuzzi G, Cravedi P, Perna A, et al. Long-Term Outcome of Renal Transplantation from  
459 Older Donors. *N Engl J Med*. 2006;354(4):343-352. doi:10.1056/NEJMoa052891
- 460 12. Husain SA, Chiles MC, Lee S, et al. Characteristics and Performance of Unilateral Kidney  
461 Transplants from Deceased Donors. *Clin J Am Soc Nephrol*. 2018;13(1):118-127.  
462 doi:10.2215/CJN.06550617
- 463 13. Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of  
464 Deceased Donor Acute Kidney Injury With Recipient Graft Survival. *JAMA Network Open*.  
465 2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634
- 466 14. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in  
467 deceased donors with acute kidney injury. *Clin Transplant*. Published online August 4,  
468 2022:e14788. doi:10.1111/ctr.14788
- 469 15. Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated  
470 with kidney allograft failure. *Kidney Int*. 2019;95(1):199-209.  
471 doi:10.1016/j.kint.2018.08.047
- 472 16. Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney  
473 injury and graft outcomes. *PLoS One*. 2022;17(3):e0264329.  
474 doi:10.1371/journal.pone.0264329
- 475 17. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney  
476 Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet.  
477 *Front Immunol*. 2020;11:833. doi:10.3389/fimmu.2020.00833
- 478 18. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated  
479 by data-independent acquisition: a new concept for consistent and accurate proteome  
480 analysis. *Mol Cell Proteomics*. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717
- 481 19. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma  
482 proteomics. *Mol Syst Biol*. 2017;13(9):942. doi:10.15252/msb.20156297
- 483 20. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of  
484 Machine Learning in Clinical Transplantation. *Transplantation*. 2021;105(4):723-735.  
485 doi:10.1097/TP.0000000000003424
- 486 21. Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply  
487 phenotyped kidney transplant recipients using artificial intelligence: an observational,  
488 international, multicohort study. *The Lancet Digital Health*. 2021;3(12):e795-e805.  
489 doi:10.1016/S2589-7500(21)00209-0
- 490 22. Fokkema M. Fitting prediction rule ensembles with R package pre. *J Stat Softw*.  
491 2020;92(1):1-30. doi:10.18637/jss.v092.i12
- 492 23. Friedman JH. Multivariate Adaptive Regression Splines. *aos*. 1991;19(1):1-67.  
493 doi:10.1214/aos/1176347963

- 494 24. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. S. *Earth: Multivariate*  
495 *Adaptive Regression Splines.*; 2011. <http://CRAN.R-project.org/package=earth>
- 496 25. UK Renal Registry. *UK Renal Registry 24th Annual Report - Data to 31/12/2020.*; 2022.  
497 <https://renal.org/audit-research/annual-report>
- 498 26. Brier GW. Verification Of Forecasts Expressed In Terms Of Probability. *Mon Weather Rev.*  
499 1950;78(1):1-3. doi:10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
- 500 27. Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney  
501 transplantation using flexible parametric modelling. *BMC Nephrol.* 2016;17(1):51.  
502 doi:10.1186/s12882-016-0264-0
- 503 28. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from  
504 Donation after Circulatory Death Donors in the United States. *J Am Soc Nephrol.*  
505 2017;28(12):3647-3657. doi:10.1681/asn.2017030238
- 506 29. Robinson C. *NHSBT Policy POL186/10. Kidney Transplantation: Deceased Donor*  
507 *Allocation.*; 2019. [https://nhsbtde.blob.core.windows.net/umbraco-assets-](https://nhsbtde.blob.core.windows.net/umbraco-assets-corp/16915/kidney-allocation-policy-pol186.pdf)  
508 [corp/16915/kidney-allocation-policy-pol186.pdf](https://nhsbtde.blob.core.windows.net/umbraco-assets-corp/16915/kidney-allocation-policy-pol186.pdf)
- 509 30. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death  
510 donor kidneys associates with adverse post-transplant outcomes. *Am J Transplant.* Published  
511 online December 8, 2021. doi:10.1111/ajt.16912
- 512 31. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the  
513 same transplant survival disadvantage for DCD and DBD kidneys. *Am J Transplant.*  
514 2015;15(3):754-763. doi:10.1111/ajt.13009
- 515 32. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.  
516 Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in  
517 vitronectin. *EMBO Rep.* 2016;17(7):982-998. doi:10.15252/embr.201541681
- 518 33. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with  
519 high levels of fibrosis in kidney grafts. *J Nephrol.* 2021;34(3):861-874. doi:10.1007/s40620-  
520 020-00886-y
- 521 34. Diepenhorst GMP, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion  
522 injury: lessons learned from animal and clinical studies. *Ann Surg.* 2009;249(6):889-899.  
523 doi:10.1097/SLA.0b013e3181a38f45
- 524 35. Arias-Cabrales CE, Riera M, Pérez-Sáez MJ, et al. Activation of final complement  
525 components after kidney transplantation as a marker of delayed graft function severity. *Clin*  
526 *Kidney J.* 2021;14(4):1190-1196. doi:10.1093/ckj/sfaa147
- 527 36. Almitairi JOM, Venkatraman Girija U, Furze CM, et al. Structure of the C1r-C1s interaction  
528 of the C1 complex of complement activation. *Proc Natl Acad Sci U S A.* 2018;115(4):768-  
529 773. doi:10.1073/pnas.1718709115

- 530 37. Awdishu L, Tsunoda S, Pearlman M, et al. Identification of Maltase Glucoamylase as a  
531 Biomarker of Acute Kidney Injury in Patients with Cirrhosis. *Crit Care Res Pract.*  
532 2019;2019:5912804. doi:10.1155/2019/5912804
- 533 38. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. *Semin Immunol.*  
534 2014;26(3):237-245. doi:10.1016/j.smim.2014.02.009
- 535 39. Hernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory kidney  
536 diseases. *Kidney Int.* 2009;76(3):262-276. doi:10.1038/ki.2009.142
- 537 40. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive  
538 estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J*  
539 *Kidney Dis.* 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237
- 540 41. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a  
541 more sensitive and more accurate marker of glomerular filtration rate than enzymatic  
542 measurements of creatinine in renal transplantation. *Nephron Physiol.* 2003;94(2):19-27.  
543 doi:10.1159/000071287
- 544 42. Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors  
545 of long-term allograft outcomes in kidney transplant recipients. *Clin Transplant.*  
546 2013;27(2):E177-83. doi:10.1111/ctr.12082
- 547 43. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a  
548 new marker of glomerular filtration rate in children independent of age and height.  
549 *Pediatrics.* 1998;101(5):875-881. doi:10.1542/peds.101.5.875
- 550 44. Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C  
551 and serum creatinine in an adult sub-Saharan African population. *BMC Clin Pathol.*  
552 2019;19:4. doi:10.1186/s12907-019-0086-7
- 553 45. Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic  
554 Kidney Disease, and Cardiovascular Risk. *Int J Endocrinol.* 2020;2020:9524839.  
555 doi:10.1155/2020/9524839
- 556 46. Park JM, Kim MY, Kim TH, Min DK, Yang GE, Ahn YH. Prolactin regulatory element-  
557 binding (PREB) protein regulates hepatic glucose homeostasis. *Biochim Biophys Acta Mol*  
558 *Basis Dis.* 2018;1864(6 Pt A):2097-2107. doi:10.1016/j.bbadis.2018.03.024
- 559 47. Gaudet P, Livstone MS, Lewis SE, Thomas PD. Phylogenetic-based propagation of  
560 functional annotations within the Gene Ontology consortium. *Brief Bioinform.*  
561 2011;12(5):449-462. doi:10.1093/bib/bbr042
- 562 48. Mohammed-Ali Z, Cruz GL, Dickhout JG. Crosstalk between the unfolded protein response  
563 and NF-κB-mediated inflammation in the progression of chronic kidney disease. *J Immunol*  
564 *Res.* 2015;2015:428508. doi:10.1155/2015/428508
- 565 49. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney  
566 Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND

- 567 MATRIX EXPANSION. *J Biol Chem.* 2001;276(52):49142-49147.  
568 doi:10.1074/JBC.M104879200
- 569 50. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal  
570 transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin*  
571 *Transplant.* 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x
- 572 51. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic  
573 allograft nephropathy after renal transplantation. *Transplant Proc.* 2004;36(10):2982-2984.  
574 doi:10.1016/j.transproceed.2004.10.038
- 575 52. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal  
576 transplantation. *Transplant Proc.* 2007;39(7):2217-2218.  
577 doi:10.1016/j.transproceed.2007.06.011
- 578 53. Czaplińska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene  
579 polymorphism and renal function are associated with apolipoprotein e concentration in  
580 patients with chronic kidney disease. *Lipids Health Dis.* 2019;18(1):1-9.  
581 doi:10.1186/s12944-019-1003-x
- 582 54. Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney  
583 disease. *J Am Med Assoc.* 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892
- 584 55. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E  
585 mutations in lipoprotein glomerulopathy. *Trends Cardiovasc Med.* 2002;12(2):67-70.  
586 doi:10.1016/S1050-1738(01)00148-7
- 587 56. Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in  
588 human iPSC-derived glia. *Sci Transl Med.* 2021;13(583):eaaz4564.  
589 doi:10.1126/scitranslmed.aaz4564
- 590 57. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,  
591 mechanisms, and therapy. *Nat Rev Neurol.* 2013;9(2):106-118.  
592 doi:10.1038/nrneurol.2012.263
- 593 58. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E  
594 genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.  
595 *PLoS Med.* 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289
- 596 59. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev*  
597 *Genomics Hum Genet.* 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507
- 598 60. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of  
599 Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung  
600 Disease. *Am J Respir Cell Mol Biol.* 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR
- 601 61. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia  
602 independent of cerebral small-vessel disease. *Neurology.* 2014;82(12):1051-1057.  
603 doi:10.1212/WNL.0000000000000251



- 604 62. Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation  
605 between ischemic and non-injured contralateral kidneys after reperfusion. *Sci Rep*.  
606 2018;8(1):8539. doi:10.1038/s41598-018-26804-8
- 607 63. Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence.  
608 *Nature Aging*. 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z
- 609 64. Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1  
610 Genotype in Calculation of Kidney Donor Risk Index. *Am J Transplant*. 2017;17(6):1540.  
611 doi:10.1111/AJT.14113
- 612 65. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of  
613 ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3
- 614 66. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation  
615 combined with data-independent acquisition. *Nat Methods*. 2020;17(12):1229-1236.  
616 doi:10.1038/s41592-020-00998-0
- 617 67. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and  
618 resources in 2019: improving support for quantification data. *Nucleic Acids Res*.  
619 2019;47(D1):D442-D450. doi:10.1093/nar/gky1106


620

## 621 **ACKNOWLEDGMENTS**

622 We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry for providing  
623 the samples and the associated clinical and demographic metadata. ; in particular we thank Sheba  
624 Ziyenge, Lewis Simmonds and Dr Sarah Cross, Dr Sergei Maslau and Mr Tomas Surik for their  
625 support on the QUOD sample selection.

626 We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry  
627 Laboratory for expert help with mass spectrometry analysis, and members of the Lindgren group  
628 at the BDI for informative discussions regarding statistical modelling.

629 FIGURES AND TABLES



630 **Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome**  
631 One kidney from each donor pair was biopsied at the back table. Donor kidney samples were selected randomly  
632 from pairs where both recipients had similar outcomes. The biopsy samples were subjected to proteomic analysis to  
633 yield a snapshot of the organ proteome before transplantation. We analyzed donor characteristics and clinical  
634 variables, recipient characteristics and protein abundances in a combined model against outcome. eGFR units for  
635 stratification given in ml/min/1.73 m<sup>2</sup>.


Donor Type	DBD			DCD		
Outcome Tertile (eGFR in ml/min/1.73 m <sup>2</sup> )	1 <sup>st</sup> : Suboptimal (eGFR≤39)	2 <sup>nd</sup> : Intermediate (40≤eGFR≤59)	3 <sup>rd</sup> : Good (eGFR≥60)	1 <sup>st</sup> : Suboptimal (eGFR≤39)	2 <sup>nd</sup> : Intermediate (40≤eGFR≤59)	3 <sup>rd</sup> : Good (eGFR≥60)
n	31	31	38	31	28	26
Donor Age, y	56.84 ± 12.29	51.32 ± 12.24	39.05 ± 14.12	55.48 ± 9.34	53.57 ± 9.75	38.31 ± 12.28
Donor Sex						
Male	15 (48.4%)	16 (51.6%)	19 (50.0%)	22 (71.0%)	16 (57.1%)	16 (61.5%)
Female	16 (51.6%)	15 (48.4%)	19 (50.0%)	9 (29.0%)	12 (42.9%)	10 (38.5%)
Donor Ethnicity						
White	30 (96.8%)	30 (96.8%)	36 (94.7%)	30 (96.8%)	28 (100.0%)	25 (96.2%)
Other	1 (3.2%)	1 (3.2%)	2 (5.3%)	1 (3.2%)	0 (0.0%)	1 (3.8%)
Donor Weight, kg	82.53 ± 18.20	76.61 ± 18.07	81.38 ± 17.72	80.58 ± 14.95	82.43 ± 17.20	78.67 ± 13.96
Donor Height, cm	168.42 ± 9.37	169.52 ± 7.67	174.82 ± 11.16	169.97 ± 7.98	171.64 ± 9.73	174.65 ± 8.98
Donor S-Cr terminal, μmol/l	86.54 ± 40.81	82.57 ± 49.65	90.19 ± 67.36	73.37 ± 19.03	70.31 ± 39.02	59.60 ± 22.39
Donor CIT, h	15.80 ± 3.88	14.20 ± 4.60	13.42 ± 4.67	13.65 ± 5.20	11.72 ± 3.55	12.80 ± 4.49
Donor COD						
Trauma	1 (3.2%)	3 (9.7%)	3 (7.9%)	4 (12.9%)	3 (10.7%)	4 (15.4%)
Other	30 (96.8%)	28 (90.3%)	35 (92.1%)	27 (87.1%)	25 (89.3%)	22 (84.6%)
Donor UKKDRI	1.41 ± 0.52	1.10 ± 0.36	0.85 ± 0.36	1.31 ± 0.37	1.21 ± 0.40	0.73 ± 0.35
Recipient Age, y	53.03 ± 12.21	52.10 ± 14.61	39.71 ± 16.03	51.90 ± 9.85	50.93 ± 11.04	44.92 ± 12.87
Recipient Sex						
Female	15 (48.4%)	8 (25.8%)	12 (31.6%)	11 (35.5%)	9 (32.1%)	5 (19.2%)
Male	16 (51.6%)	23 (74.2%)	26 (68.4%)	20 (64.5%)	19 (67.9%)	21 (80.8%)
Recipient Ethnicity						
White	24 (77.4%)	21 (67.7%)	29 (76.3%)	22 (71.0%)	23 (82.1%)	20 (76.9%)
Other	7 (22.6%)	10 (32.3%)	9 (23.7%)	9 (29.0%)	5 (17.9%)	6 (23.1%)
Recipient Posttransplant Kidney Function (mean eGFR, ml/min/1.73 m <sup>2</sup> )						
3 months	29.71 ± 12.06	50.32 ± 17.28	78.54 ± 25.97	31.72 ± 12.24	46.50 ± 10.34	77.88 ± 18.57
12 months	26.58 ± 11.98	49.58 ± 6.10	85.58 ± 35.84	25.10 ± 12.01	48.24 ± 6.29	80.26 ± 15.91

636 **Table 1: Donor and recipient clinical and demographic variables**


637 Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile.

638 Numerical variables are given ± standard deviation. Categorical variables are given alongside percentage of total

639 cohort



640 **Figure 2: Donor and recipient clinical and demographic data association with recipient 12 month eGFR rank**  
 641 Single-linkage hierarchical clustering of curated, imputed clinical variables by relative association strength (taking  
 642 distance as 1-association). The outcome variable (ranked recipient eGFR at 12 months post-transplantation) is  
 643 highlighted in red.



644 **Figure 3: Unbiased analysis of pretransplant kidney proteomes and cluster associations**

645 A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by Principal Component Analysis.

646 Top Left: Samples were assigned to four clusters by k-means. Bottom & Right: There was a difference in the

647 distribution of DBD and DCD donors across clusters, with the DBD donors being more heavily concentrated in


648 Cluster 2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)

649 B: There were no associations between proteome clusters and most donor and recipient factors, except for mildly

650 significant differences in donor BMI and creatinine (selected comparisons shown; left-right, top-bottom: donor type,

651 recipient 12-month posttransplant eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at

652 retrieval).



653 **Figure 4: Age and combined age:protein related associations link to construction of age-modulated immune**  
 654 **metabolic biological networks**

655 A: Prediction Rule Ensemble (PRE) modelling was performed in an iterative manner to select protein and clinical  
 656 variable associations with ranked eGFR. At each iteration, only proteins not previously featured in a model were  
 657 considered. The rules found across all iterations were dominated by donor age terms.

658 B: Cumulative protein features identified at each iteration. Black line: all features identified by feature selection  
 659 approach. Blue line: features passing the secondary filter for predictive power and accuracy.



660 C: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned  
 661 cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.

662

<b>Cluster Label</b>	<b>Top 3 Shared Pathways</b>
Immune Regulation and Complement Activation	Immune System Innate Immune System Regulation Of Complement Cascade
Protein Metabolism and Regulation	Metabolism Of Proteins Post-translational Protein Modification Mitochondrial Translation Elongation
Metabolism	Metabolism Metabolism Of Amino Acids And Derivatives Pyruvate Metabolism And Citric Acid (TCA) Cycle
Apoptosis	Developmental Biology Role Of GTSE1 In G2/M Progression After G2 Checkpoint Apoptosis
Striated Muscle Contraction	Striated Muscle Contraction


663 **Table 2: Shared Pathway Network Clusters**

664 Proteins in Figure 4C were clustered by pathway membership, forming 4 major clusters and one minor cluster  
665 (Striated Muscle Contraction). We assigned summary labels to each cluster based on the top 3 pathways with shared  
666 membership in each cluster.



667 **Figure 5: Modelled associations between proteins and kidney transplant outcome change with donor age**  
 668 A: Ages at which the predicted probability of sub-median outcome is most different between the 10<sup>th</sup> percentile and  
 669 90<sup>th</sup> percentile of protein abundance.  $x$  axis: age at which difference is greatest (i.e. when protein has greatest  
 670 effect).  $y$  axis: greatest difference.  
 671 Proteins above  $x=0$  are modelled as having a more negative association with outcome when the protein abundance is  
 672 high, at that donor age. Proteins below  $x=0$  are modelled to have a more positive association with outcome when  
 673 protein abundance is high, at that donor age.  
 674 Proteins with absolute net difference  $>0.5$  are labelled, as well as the selected proteins VTN, PREB, APOE and  
 675 CST3.  
 676 The inset graphs indicate how the prediction of sub-median outcome (“P(S-M outcome)”;  $y$  axes) changes with  
 677 donor age ( $x$  axes) for labelled proteins. Black trace: prediction at median protein abundance. Purple trace:  
 678 prediction at 90<sup>th</sup> percentile of protein abundance. Orange trace: prediction at 10<sup>th</sup> percentile of protein abundance.  
 679 The corresponding point on the main figure thus indicates the age at which the difference between orange and purple  
 680 lines is greatest.  
 681 B: Summary of feature selection and modelling analysis





683 **Figure 6: Orthogonal validation confirms age-modulated immuno-metabolic proteins predict 12-month**  
684 **transplant outcomes**

685 A: Validation of models in test dataset. Models are plotted in order of decreasing Brier score (mean squared  
686 prediction error) *difference* between test and train data along the x axis. The lower two traces indicate the Brier score  
687 in train (purple) and test (green) data. The upper two traces indicate the AUC from the corresponding ROC analyses  
688 in train (orange) and test (blue) data.

689 B-E: Validation of four selected proteins. Left-Right: VTN, PREB, APOE, CST3.

690 B: Final ROC curves and AUC values for models trained on each protein (and donor age) against test data. The  
691 dotted line indicates the original performance against training data.

692 C: Change in the prediction of sub-median outcome (“P(S-M Outcome)”; y axes) with donor age (x axes) for each  
693 protein. Black trace: prediction at median protein abundance. Purple trace: prediction at 90<sup>th</sup> percentile of protein  
694 abundance. Orange trace: prediction at 10<sup>th</sup> percentile of protein abundance. (These are the same as the inset graphs  
695 in Figure 5). The light grey and dark grey vertical lines, respectively, indicate the corresponding ‘younger’ and  
696 ‘older’ sampled ages for the western blots below.

697 D: Western blots comparing younger (age  $\leq 49$ ) and older (age  $\geq 58$ ) donors between Good Outcome (GO;  
698 eGFR  $\geq 60$ ) and Suboptimal Outcome (SO; eGFR  $\leq 40$ ) outcome tertiles. Top row: representative western blots  
699 (n=5 per group) from comparison of younger donors. Middle row: representative western blots (n=5 per group) from  
700 comparison of older donors. Bottom row: result values for all quantified samples relative to the GO mean. Error bars  
701 indicate  $\pm 1$  standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-  
702 values (\*\*\*:  $< 0.001$ , \*:  $< 0.05$ ).

703 E: Predicted outcome for six paired Left (L) and Right (R) kidneys from three donors. x axes: recipient eGFR at 12  
704 months (i.e. actual outcome). y axes: predicted probability of sub-median outcome (“P(S-M Outcome)”) using  
705 models trained on each protein with donor age. Vertical dotted line indicated median outcome (eGFR = 50).  
706 Horizontal dotted line indicates P(Sub-Median Outcome) = 0.5